# lung adenocarcinoma (LUAD) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 65595
- Completion tokens: 38412
- Reasoning tokens: 11338
- Total tokens: 104007
- API requests reported: 5
- Elapsed seconds: 129.465
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: MiniMax

---
<think>The user wants a multidimensional, evidence-grounded interpretation of a prognostic transcriptomic dataset in lung adenocarcinoma (LUAD). Let me carefully analyze what's in front of me.

**Critical data observations from the ledger:**

1. **Extreme HR values**: Many genes have HR = 5.1847055e+21 (an astronomically large value), with P=0 and FDR=0. This is clearly a computational artifact—likely convergence to a boundary in Cox PH regression when a gene is expressed in only a few samples (often 1-2), creating quasi-complete separation. The model is not identifiable, so the HR diverges to numerical infinity.

2. **Direction counts**: 96 risk-associated (HR>1), 4 protective-associated (HR<1)
   - Protective: RBMXP1 (HR=0.2118), TCP10L3 (HR=1.93e-22, i.e., protective direction), CRNDE (HR=0.716), CMAHP (HR=0.7055)
   - Wait, TCP10L3 has HR=1.93e-22 which is far less than 1, so it's protective, but the magnitude is clearly degenerate.

3. **Duplicate issue**: Y_RNA has 163 rows (direction-conflict), LINC00707 has 2 rows. The ledger shows 100 unique genes from 263 input rows.

4. **Extreme P=0 and FDR=0 values**: These are not legitimate. True P values cannot be exactly 0; these represent numerical underflow. The Cox regression likely had boundary issues.

5. **Many pseudogenes and non-coding RNAs**: RBMY1F, FAM9A, TCP10L3, TEX13A, RBMY2AP, CDY10P, USP9YP3, VENTXP7, AMMECR1LP1, RBMXP1, MIR509-1, MIR3924, MIR8065, MIR6862-1, FAS-AS1, CRNDE, various RP11 lincRNAs. Many are Y-chromosome or testis-specific.

6. **A few "real" protein-coding genes with reasonable HRs (1.1-1.5)**:
   - PITX3 (HR=1.429, FDR=3.49e-11)
   - DKK1 (HR=1.475, FDR=3.55e-07) — Wnt antagonist
   - TLE1 (HR=1.484, FDR=2.46e-05) — Wnt/Notch transcription factor
   - KRT6A (HR=1.39, FDR=2.78e-04) — keratin
   - LDLRAD3 (HR=1.42, FDR=2.23e-04)
   - VAX1 (HR=1.335, FDR=9.25e-06)
   - FUT4 (HR=1.403, FDR=2.93e-04) — fucosyltransferase
   - RHOF (HR=1.403, FDR=4.0e-04) — Rho GTPase
   - RGS20 (HR=1.352, FDR=5.79e-04) — G protein signaling
   - CREG2 (HR=1.332, FDR=1.63e-04)
   - RHCG (HR=1.290, FDR=4.73e-04)
   - OR10J6P (HR=1.291, FDR=1.84e-04) — olfactory receptor pseudogene

7. **GO/KEGG selection**:
   - GO: Regulation of Wnt signaling pathway (GO:0030111)
   - Positive regulation of Wnt signaling pathway
   - Planar Cell Polarity pathway (GO:2000096)
   - Cell Junction Disassembly (GO:0150146)
   - KEGG: Mannose type O-glycan biosynthesis, Wnt signaling pathway, Glycosphingolipid biosynthesis

This is interesting because DKK1 and TLE1 are bona fide Wnt regulators, and the pathway annotation captured that.

**Data quality warning first**:

The dataset is degenerate. Most HRs are infinite (5.185e+21) and P-values/FDRs are exactly 0, which is mathematically impossible. This indicates:
- Cox PH model quasi-complete separation (gene expressed in too few events/non-events)
- Numerical overflow / boundary convergence
- No penalization (ridge/LASSO) applied
- Pseudogenes and lncRNAs with sporadic expression patterns

I must follow the developer policy: state the data-quality warning, then continue with exploratory interpretation using available annotations, pathways, literature. Separate unreliable direct statistical evidence from externally supported hypotheses.

Let me plan the response:

1. **Data quality warning** — be explicit about the degenerate statistics
2. **Overall biological interpretation** — given the data, focus on the small set of protein-coding genes with credible HRs
3. **Core biological programs** — up to 5 programs, based on what's biologically interpretable
4. **Key genes and interaction modules** — focus on DKK1, TLE1, PITX3, KRT6A, RHOF, RGS20, FUT4, LDLRAD3, VAX1, CREG2
5. **Validation priorities**
6. **Evidence grounding** — clearly distinguish input statistics from external annotation
7. **Limitations**

Let me identify biological programs from the credible subset:

**Program 1: Wnt signaling dysregulation**
- DKK1 (Wnt antagonist, HR=1.475 risk)
- TLE1 (Groucho/TLE co-repressor for Wnt/Notch, HR=1.484 risk)
- Pathway annotation: GO:0030111, Positive Regulation of Wnt, KEGG: Wnt signaling
- DKK1 is a Dickkopf family secreted Wnt inhibitor — paradoxically risk-associated. In cancer, DKK1 is known to promote immune evasion and is often associated with poor prognosis in LUAD.
- TLE1 is a Groucho family transcriptional co-repressor that modulates Wnt/β-catenin and Notch signaling.

**Program 2: Epithelial identity and keratinization**
- KRT6A (HR=1.390 risk)
- KRT6A is a keratin expressed in basal/squamous epithelia. In LUAD, squamous transdifferentiation (especially in EGFR-mutant or post-treatment) is associated with worse prognosis.

**Program 3: Small GTPase / cytoskeletal remodeling**
- RHOF (HR=1.403 risk) — Rho family GTPase
- RGS20 (HR=1.352 risk) — RGS for Gα signaling, modulates G-protein signaling
- VAX1 (HR=1.335 risk) — transcription factor associated with cell migration/invasion in some contexts
- CREG2 (HR=1.332 risk) — may modulate cell adhesion

**Program 4: Glycosylation / fucosylation**
- FUT4 (HR=1.403 risk) — α1,3-fucosyltransferase, involved in selectin ligand synthesis
- KEGG: Mannose type O-glycan biosynthesis, Glycosphingolipid biosynthesis
- FUT4 promotes selectin-mediated adhesion and metastasis

**Program 5: Transcription factor programs in development/differentiation**
- PITX3 (HR=1.429 risk) — pituitary homeobox transcription factor
- VAX1 (HR=1.335 risk) — ventral anterior homeobox
- These are developmental TFs with limited normal tissue expression but associated with oncogenic roles

**Program 6: Cell junction / planar cell polarity**
- TLE1 modulates Wnt/PCP
- The GO annotation includes Planar Cell Polarity Pathway (GO:2000096) and Cell Junction Disassembly (GO:0150146)

Let me consolidate to ≤5 programs:

1. **Wnt signaling dysregulation** (DKK1, TLE1, with PCP/junction disassembly tie-in)
2. **Glycosylation and cell-surface modification** (FUT4, KRT6A in epithelial remodeling)
3. **Small GTPase / cytoskeletal & G-protein signaling** (RHOF, RGS20)
4. **Developmental transcription factor reactivation** (PITX3, VAX1, CREG2)
5. **lncRNA/pseudogene-dominated risk signature** (ITGB1-DT, CRNDE, FAS-AS1, etc.) — most are statistically unreliable but the literature supports some.

Actually, let me think more carefully. The pathway annotation specifically called out "Planar Cell Polarity Pathway" and "Cell Junction Disassembly" and "Glycosphingolipid biosynthesis / Mannose type O-glycan biosynthesis". These were selected because of the input genes. Which input genes map to these?

- Cell Junction Disassembly: Possibly TLE1, LDLRAD3, RHOF
- Planar Cell Polarity: Wnt-related (TLE1, DKK1 indirectly)
- Glycosphingolipid biosynthesis: FUT4
- Mannose O-glycan: FUT4, possibly KRT6A indirectly

Let me write the response now. I need to be careful to:
- Lead with the data quality warning
- Be honest about which statistics are credible
- Focus on the small subset of biologically interpretable genes
- Distinguish input evidence from external annotation
- Mark unsupported claims as such
- Not enumerate all 100 genes

Let me draft the response.

---

Format: Markdown with sections. The developer policy says I should follow user's requested format and scope, and the user asked for 6 specific sections. I'll structure around those 6.

Length: comprehensive but not bloated. The user explicitly said "Do not optimize for length or number of biological concepts mentioned." So I should be focused.

Let me write it now.</think>

# Multidimensional Interpretation — LUAD Prognostic Transcriptomic Signature

## 0. Data-quality warning (read first)

Before any biological reading, the uploaded Cox OS statistics must be flagged as **degenerate and not directly interpretable as ordinary hazard ratios**:

- **96 / 100** selected genes carry `HR = 5.185 × 10²¹`, `P = 0`, `FDR = 0` (exact). True P-values cannot equal zero; these are numerical underflow/overflow artefacts.
- The pattern (one identical massive HR repeated across dozens of unrelated lncRNAs, pseudogenes, Y-chromosome–linked transcripts, snRNAs, and `UNMAPPED_ENSEMBL_*` identifiers) is the classical signature of **quasi-complete separation** in Cox PH regression — almost certainly produced by genes that are detectably expressed in only 1–2 patients (often only in the events group). The likelihood blows up, the HR saturates at the numerical limit, and the Wald P collapses to zero.
- `TCP10L3` shows the mirror artefact on the protective side (`HR ≈ 10⁻²²`).
- `Y_RNA` is reported with **163 duplicate / direction-conflicting rows**, indicating the probe or feature collapsed across many aliases.
- **Direct statistical inference from these extreme HR/P/FDR values is not valid.** Any ranking, magnitude comparison, or "biologically meaningful HR" claim based on these specific rows should be treated as unreliable.

Below I therefore (a) read the **moderate-HR protein-coding subset** as the only directly usable input evidence, (b) treat the extreme-HR lncRNA/pseudogene rows as hypothesis-generating only, and (c) clearly label which conclusions rest on each tier. Independent-cohort replication is **not available**; the synthesis block confirms `INDEPENDENT COHORT VALIDATION: status=not_available`.

---

## 1. Overall biological interpretation

Once the saturated rows are excluded, the **biologically interpretable LUAD prognostic signal is concentrated in a small set of protein-coding genes with HRs in the 1.2–1.5 range and finite FDRs (DKK1, TLE1, PITX3, KRT6A, FUT4, LDLRAD3, VAX1, RHOF, RGS20, CREG2, RHCG)**. Their convergent theme is **disrupted epithelial differentiation coupled with active Wnt-pathway remodelling, altered glycosylation/fucosylation of the cell surface, and cytoskeletal/G-protein signalling rewiring that supports migration and invasion** — the canonical features of a poor-prognosis, mesenchymal-shifted LUAD phenotype. A second, much larger but statistically unreliable layer consists of **testis-/Y-chromosome-restricted transcripts, lncRNAs (ITGB1-DT, CRNDE, FAS-AS1), and pseudogenes** that almost certainly track with the expression of their cognate protein-coding neighbours or with patient-level confounders rather than acting as independent prognostic drivers.

In short**: the input does not support a novel "100-gene prognostic program"; it supports a smaller, biologically coherent poor-prognosis signature embedded within a much larger, statistically artefactual signal.

---

## 2. Core biological programs

### Program A — Wnt signalling re-wiring (risk-associated)
- **Direction**: adverse overall survival for high expression.
- **Supporting input genes**: **DKK1** (HR 1.475, FDR 3.5 × 10⁻⁷), **TLE1** (HR 1.484, FDR 2.5 × 10⁻⁵). Both reach genome-wide significance and have finite, biologically plausible effect sizes.
- **Best-aligned standardised terms**: GO:0030111 "regulation of Wnt signalling pathway"; GO:2000096 "planar cell polarity pathway"; KEGG `Wnt signaling pathway`.
- **Why these genes fit together**: DKK1 is a secreted Wnt antagonist that paradoxically marks poor prognosis in LUAD by promoting immune exclusion and β-catenin-independent migration. TLE1 is a Groucho/TLE co-repressor that interfaces Wnt/β-catenin and Notch transcriptional outputs and is itself a known LUAD prognostic marker.
- **Evidence strength**: input evidence is the strongest in the dataset (finite HR, FDR ≪ 0.05). External literature supports DKK1 and TLE1 as LUAD prognostic factors. **Limitation**: only two genes anchor this program; the Wnt-pathway annotation in the input pack was driven almost entirely by these two.

### Program B — Cell-surface glycosylation and fucosylation (risk-associated)
- **Direction**: adverse OS.
- **Supporting input genes**: **FUT4** (HR 1.403, FDR 2.9 × 10⁻⁴) and **KRT6A** (HR 1.390, FDR 2.8 × 10⁻⁴) as a keratinisation/epithelial-remodelling correlate.
- **Best-aligned standardised terms**: KEGG `Mannose type O-glycan biosynthesis`, KEGG `Glycosphingolipid biosynthesis`; GO MF "protein binding" / molecular-function cluster dominated by FUT4 and KRT6A in the retrieved module.
- **Why these genes fit together**: FUT4 (α1,3-fucosyltransferase) builds selectin-ligand epitopes that enable adhesion, extravasation and metastasis; KRT6A marks a basal/squamous transdifferentiation state that frequently co-occurs with aggressive, therapy-resistant LUAD.
- **Evidence strength**: FUT4 is a published metastasis-associated glycosyltransferase; the KEGG/Reactome recurrence is genuine external support. **Limitation**: FUT4 and KRT6A do not directly bind each other; their relationship is pathway co-membership / co-phenotype, not physical interaction.

### Program C — Cytoskeletal and G-protein signalling (risk-associated)
- **Direction**: adverse OS.
- **Supporting input genes**: **RHOF** (HR 1.403, FDR 4.0 × 10⁻⁴), **RGS20** (HR 1.352, FDR 5.8 × 10⁻⁴), **VAX1** (HR 1.335, FDR 9.2 × 10⁻⁶), **CREG2** (HR 1.332, FDR 1.6 × 10⁻⁴).
- **Best-aligned standardised terms**: Reactome `G alpha (i) signalling events` and `G alpha (z) signalling events` for RGS20; GO `actin filament organization`, `regulation of small GTPase mediated signal transduction` for RHOF; GO `Cell Junction Disassembly` (GO:0150146) at the module level.
- **Why these genes fit together**: RHOF is a Rho-family GTPase that drives actin reorganisation and migration; RGS20 tunes heterotrimeric G-protein signalling that feeds the same cytoskeletal circuits; VAX1 is a homeobox transcription factor linked to migration/invasion programmes; CREG2 is a secreted glycoprotein that modulates adhesion. Their convergent direction supports an invasion/motility prognostic module.
- **Evidence strength**: RHOF has independent AML prognostic literature (PMID 34405015) but LUAD-specific replication is **not** established in the provided evidence; the Reactome recurrence for RGS20 is genuine external support. **Limitation**: STRING network records for RHOF and VAX1 are single-link (one partner each) and should not be read as a multi-gene LUAD interaction module.

### Program D — Developmental transcription-factor reactivation (risk-associated)
- **Direction**: adverse OS.
- **Supporting input genes**: **PITX3** (HR 1.429, FDR 3.5 × 10⁻¹¹ — strongest finite input signal), **VAX1** (HR 1.335, FDR 9.2 × 10⁻⁶).
- **Best-aligned standardised terms**: not captured in the input GO/KEGG batch; closest are general "developmental protein" and homeodomain annotations in UniProt/mygene.
- **Why these genes fit together**: Both are tissue-restricted homeobox transcription factors (PITX3 in midbrain/dopaminergic neurons; VAX1 in ventral forebrain) with minimal baseline expression in lung. Their appearance as adverse-prognosis LUAD markers fits the broader oncogene "ectopic developmental TF reactivation" pattern.
- **Evidence strength**: PITX3 has the most significant finite P/FDR in the entire dataset, but this is one gene, and **independent LUAD replication was not performed** in the supplied evidence. **Limitation**: the program currently rests on only two genes with no pathway-level convergence in the retrieved ontologies.

### Program E — Long non-coding / pseudogene risk tag (statistically unreliable, hypothesis-generating)
- **Direction**: nominally adverse OS, but the HR/P statistics are saturated.
- **Supporting input genes (illustrative, not exhaustive)**: ITGB1-DT, CRNDE, FAS-AS1, multiple RP11 lincRNAs, Y-chromosome transcripts (RBMY1F, FAM9A, RBMY2AP, USP9YP3, TEX13A, VENTXP7, TTTY4C, CDY10P), testis-restricted pseudogenes (TCP10L3, AMMECR1LP1).
- **Best-aligned standardised terms**: Reactome `Formation of HIV elongation complex…` / `RNA Pol II CTD phosphorylation` clusters containing CTD-2066L21.1/.2, CTD-2151L9.2, CTD-2534I21.9 — these are *C-terminal domain* phosphatase/kinase gene names misparsed, not a meaningful HIV pathway.
- **Why they cluster together**: not because of a coherent biology — the saturation reflects sparse expression in a small number of patients. The lncRNAs ITGB1-DT and CRNDE do have LUAD/breast-cancer literature (PMID 34906142; PMID 37690573) supporting adverse prognosis.
- **Evidence strength**: **insufficient evidence** as an independent program from the input statistics; literature support is limited to ITGB1-DT and CRNDE individually. **Limitation**: extremely high risk of confounding by sex (Y-linked genes), tumour purity, and platform drop-out.

---

## 3. Key genes and interaction modules (≤ 10)

| # | Gene | Direction in input | Role in programs | Proposed relationship type |
|---|------|--------------------|------------------|----------------------------|
| 1 | **DKK1** | Risk, HR 1.475 | A (Wnt) | Pathway co-membership (Wnt), regulatory; not a physical interactor of TLE1 in retrieved records. |
| 2 | **TLE1** | Risk, HR 1.484 | A (Wnt), C (junction disassembly) | Pathway co-membership (Wnt, Notch, PCP); STRING edges to VAX1 partner ASXL2 are indirect. |
| 3 | **PITX3** | Risk, HR 1.429 | D (developmental TF) | No direct interaction recovered; co-occurrence via "ectopic TF" pattern only. |
| 4 | **FUT4** | Risk, HR 1.403 | B (glycosylation) | STRING edges to B3GNT3 / B4GALT1 are co-membership in glycosyltransferase family, **not** direct binding. |
| 5 | **KRT6A** | Risk, HR 1.390 | B (epithelial remodelling) | Pathway co-membership with squamous/basal keratins. |
| 6 | **RHOF** | Risk, HR 1.403 | C (cytoskeleton) | STRING: ACTN1, ARHGAP1 partners — co-membership / regulatory; no high-confidence physical interaction in retrieved data. |
| 7 | **RGS20** | Risk, HR 1.352 | C (G-protein signalling) | STRING high-confidence interactors GNAZ, GNB5, GNAI2, GNAQ — these are direct physical/functional interactions per STRING scores 0.80–0.95; Reactome supports Gα(i)/Gα(z) signalling. |
| 8 | **ITGB1-DT** | Risk (saturated HR) | E (lncRNA risk tag) | Literature (PMID 34906142) supports an ITGB1-DT/ARNTL2 axis in LUAD — **literature co-occurrence / putative regulatory**, not a confirmed physical interaction. |
| 9 | **CRNDE** | Protective, HR 0.716 | E (lncRNA) | One of the few statistically non-saturated protective associations; direction is internally consistent. **Caveat**: CRNDE is reported as oncogenic in other cancers, so its protective direction in this LUAD cohort is **exploratory** until replicated. |
| 10 | **LDLRAD3** | Risk, HR 1.420 | C (adhesion / signalling) | STRING: APP partner — co-membership / regulatory only. |

Explicit non-claims: no direct physical PPI between any pair in the table is supported by the retrieved evidence pack; the strongest interaction evidence is RGS20 ↔ GNAZ/GNB5/GNAI2/GNAQ from STRING (high confidence). Everything else is **pathway co-membership, co-expression, or literature co-occurrence**, not a validated physical interaction.

---

## 4. Validation priorities (≤ 5)

1. **DKK1 / TLE1 axis as a LUAD Wnt prognostic module — *Mechanistic hypothesis*.**
   - *Why prioritise*: Only program in this dataset anchored by two input genes with finite, genome-wide-significant HRs and convergent external pathway annotation.
   - *Input evidence*: HR 1.475 and HR 1.484, FDRs of 3.5 × 10⁻⁷ and 2.5 × 10⁻⁵.
   - *External evidence*: GO:0030111 / KEGG Wnt pathway; published LUAD prognostic reports for both genes individually.
   - *Next step*: multivariate Cox with clinical covariates (stage, smoking, EGFR/KRAS status) in the same cohort, then IHC validation of DKK1 and TLE1 on a TMA with OS outcome.
   - *Status*: **Supported hypothesis**, not established.

2. **FUT4 + KRT6A as a combined glycosylation / squamous-shift prognostic score — *Biomarker*.**
   - *Why prioritise*: Combines a mechanistically interpretable glycosylation enzyme with an epithelial-state marker that are biologically complementary.
   - *Input evidence*: HRs 1.403 and 1.390, FDRs ≪ 0.001.
   - *External evidence*: KEGG mannose-type O-glycan and glycosphingolipid biosynthesis; published FUT4 / selectin-ligand metastasis biology.
   - *Next step*: build a two-gene score; test against an independent LUAD OS cohort (e.g., TCGA-LUAD as anchor) with a pre-specified hypothesis.
   - *Status*: **Exploratory hypothesis**; the existence of a drug (no clinically validated FUT4 inhibitor is established here) does not constitute therapeutic evidence.

3. **RGS20 / RHOF / VAX1 cytoskeletal-G-protein module — *Interaction / network hypothesis*.**
   - *Why prioritise*: Convergent direction across three biologically related genes plus the highest-confidence STRING network evidence in the pack (RGS20 ↔ GNAZ/GNB5).
   - *Input evidence*: HRs 1.352, 1.403, 1.335, FDRs ≤ 6 × 10⁻⁴.
   - *External evidence*: Reactome Gα(i)/Gα(z) signalling for RGS20; GO actin/GTPase terms for RHOF; VAX1 STRING partner ASXL2 only.
   - *Next step*: co-IP of RGS20 with GNAZ/GNB5 in LUAD cell lines, migration assays after RHOF knockdown, and OS validation in an independent cohort.
   - *Status*: **Exploratory hypothesis**.

4. **Sex / Y-chromosome transcript confound check — *Confounding or composition check*.**
   - *Why prioritise*: A large fraction of the saturated "risk" rows are Y-linked (RBMY1F, FAM9A, RBMY2AP, USP9YP3, TEX13A, TTTY4C, CDY10P, VENTXP7). Sex is a known LUAD prognostic covariate (LUAD is more common and often more aggressive in different sex strata).
   - *Input evidence*: extreme HRs that are statistical artefacts; the only direct signal is that they are flagged risk.
   - *External evidence*: well-established male/female differences in LUAD incidence and outcome; Y-chromosome gene expression in males is uninformative.
   - *Next step*: re-run Cox stratified by sex, and exclude Y-linked features. The "100-gene signature" almost certainly collapses once sex is properly handled.
   - *Status*: **Established methodological concern** that should be acted on before any downstream interpretation.

5. **ITGB1-DT / CRNDE lncRNA validation — *Biomarker (exploratory)*.**
   - *Why prioritise*: These two lncRNAs have the most credible published LUAD/breast-cancer evidence (PMID 34906142; PMID 37690573) among the saturated HR rows, yet their input statistics here are unreliable.
   - *Input evidence*: saturated HR (ITGB1-DT), HR 0.716 protective (CRNDE).
   - *External evidence*: explicit LUAD and breast-cancer prognostic reports.
   - *Next step*: qPCR-based OS validation in an independent LUAD cohort, separately for each lncRNA.
   - *Status*: **Exploratory hypothesis**; do not interpret CRNDE's protective direction as causal without replication.

---

## 5. Evidence grounding

- **Direct input evidence (this dataset)**: only the ~10 protein-coding genes with HRs in 1.2–1.5 and finite FDRs are interpretable. DKK1, TLE1, PITX3, VAX1, KRT6A, FUT4, LDLRAD3, RHOF, RGS20, CREG2, RHCG, CMAHP, CRNDE, RBMXP1.
- **Pathway / ontology evidence**: GO:0030111, GO:2000096, GO:0150146, KEGG Wnt / Mannose-type O-glycan / Glycosphingolipid — these were selected because of DKK1, TLE1, FUT4 and the junction-disassembly cluster; they provide **independent ontologic support** for programs A and B but not for E.
- **Protein / regulatory network evidence**: the only high-confidence direct interactions are RGS20–GNAZ/GNB5/GNAI2/GNAQ (STRING 0.80–0.95). All other listed STRING partners (ACTN1, ARHGAP1 for RHOF; APP for LDLRAD3; ASXL2 for VAX1; B3GNT3/B4GALT1 for FUT4) are **single-edge co-membership hints**, not multi-gene LUAD modules. Reactome Gα(i)/Gα(z) signalling is genuine external support for RGS20.
- **Disease-association evidence**: cBioPortal / Open Targets / ClinVar records exist for ~half the genes, but no independent LUAD-specific survival replication statistic is supplied. These are **contextual disease associations, not survival replication**.
- **Expression / tissue evidence**: GTEx for RGS20 shows dominant brain expression with low lung signal, reinforcing the "ectopic" pattern; this is supportive for the reactivation framing but is not a survival replication.
- **Drug / therapeutic evidence**: ChEMBL/CIViC return only a handful of records (16/100 and 1/100 respectively); none are validated LUAD therapeutic targets. The mere existence of a chemical probe or trial reference must not be treated as therapeutic evidence for these specific genes in LUAD.
- **Literature evidence**: PMID 34906142 (ITGB1-DT/ARNTL2 in LUAD), PMID 37690573 (ITGB1-DT in breast cancer), PMID 34405015 (RhoF in AML), PMID 40124684 (ferritinophagy in NSCLC), PMID 42216026 (KRT6A in alopecia), PMID 35022708, PMID 31065785, PMID 36983764, PMID 34906142 — useful for biological plausibility, not for survival replication of the input HRs.
- **Conflicts**: CRNDE is reported as oncogenic in most published cancers but is *protective* (HR 0.716) in this LUAD cohort — flagged as exploratory and unresolved. DKK1 is a Wnt antagonist yet its high expression is risk-associating here, which fits the known "DKK1 promotes immune evasion" literature but conflicts with a naive "Wnt inhibitor = protective" model.

---

## 6. Limitations and alternative explanations (≤ 5)

1. **Quasi-complete separation / sparse-event bias.** The dominant cause of the saturated HRs is genes expressed in a handful of patients. Re-running Cox with Firth penalisation, ridge penalisation, or excluding features with < N events would almost certainly remove ~80 % of the "risk" list.
2. **Sex / Y-chromosome confounding.** A non-trivial fraction of the input signature is Y-linked and therefore a surrogate for male sex. Stratification by sex, or removal of Y-linked features, is required before any claim of a LUAD-specific adverse signature is made.
3. **Tumour purity, stromal/immune composition, and stage.** DKK1 in particular is heavily influenced by tumour immune microenvironment. Without adjustment for purity, stage, and treatment, the prognostic effect may reflect immune-cold biology rather than tumour-intrinsic Wnt re-wiring.
4. **Batch / platform artefacts and probe mis-mapping.** `Y_RNA` collapsing across 163 rows, multiple `UNMAPPED_ENSEMBL_*` identifiers, and pseudogene-rich entries (RBMXP1, RBMY2AP, AMMECR1LP1) suggest a substantial fraction of the table is platform noise rather than biology.
5. **Association-vs-causation.** All conclusions here are Cox-derived associations. No claim of causality is supported; functional experiments (CRISPR, RNAi, small-molecule inhibition) are required before any gene in this list can be promoted from biomarker to therapeutic target.

---

**Bottom line**: the biologically usable content of this dataset is a small Wnt-centred (DKK1, TLE1) plus glycosylation/cytoskeletal (FUT4, KRT6A, RHOF, RGS20, VAX1) adverse-prognosis signature in LUAD. The much larger apparent 100-gene "risk" list is dominated by Cox-regression separation artefacts and should not be reported as a prognostic program until the model is re-fit with a penalised estimator and sex/purity/stage are properly accounted for.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=70, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
